CYP2C9、CYP2C19、CYP3A4基因多态性对磺脲类降糖药代谢的影响

中国临床药理学与治疗学 ›› 2012, Vol. 17 ›› Issue (5): 582-587.

CYP2C9、CYP2C19、CYP3A4基因多态性对磺脲类降糖药代谢的影响

李赟^1,2, 何芳¹, 曾彩雯¹, 刘林林¹, 夏春华¹

¹南昌大学医学院临床药理研究所,南昌 330006,江西;
²江西护理职业技术学院, 南昌 330201,江西

收稿日期:2012-01-03 修回日期:2012-04-24 出版日期:2012-05-26 发布日期:2012-05-28
通讯作者: 夏春华,男,教授,硕士生导师,主要从事临床药理学与药物代谢动力学研究。Tel: 0791-86360654 E-mail: xch720917@yahoo.com.cn
作者简介:李赟,女,硕士研究生,研究方向:临床药理学与药物代谢动力学。Tel: 0791-86360654 E-mail: 425431334@qq.com
基金资助:
国家自然科学基金(81060275, 81160411);国家十二五重大专项(2011ZX09302-007-03);江西省自然科学基金(2009GZY0141)

Effect of CYP2C9, CYP2C19, CYP3A4 polymorphism on metabolism of sulfonyluea antidiabetic drugs

LI Yun^1,2, HE Fang¹, ZENG Cai-wen¹, LIU Lin-lin¹, XIA Chun-hua¹

¹Institute of Clinical Pharmacology, Medical College of Nanchang University,Nanchang 330006, Jiangxi,China;
²Jiangxi Nursing Occupation Technology College, Nanchang 330201, Jiangxi,China

Received:2012-01-03 Revised:2012-04-24 Online:2012-05-26 Published:2012-05-28

摘要/Abstract

摘要： 磺脲类口服降糖药在人体内主要经过肝脏代谢。肝脏中的细胞色素氧化酶P450是一种重要的药物代谢酶系统,在人群中存在基因多态性,导致药物疗效和不良反应在个体间存在着较大的差异。本文将对CYP450中的几种重要的代谢酶亚型CYP2C9、CYP2C19、CYP3A4的基本结构、基因多态性、种族差异及其对磺脲类降糖药代谢的影响作一综述。

关键词: CYP2C9, CYP2C19, CYP3A4, 磺脲类降糖药, 药物代谢

Abstract: Sulfonylurea oral antidiabetic drugs were mainly metabolized by hepatic cytochrome P450 in human.Cytochrome P450 is one kind of important drug metabolizing enzymes in human and exhibits genetic polymorphism, which usually results in the difference of efficacy and adverse reaction among individuals.The purpose of this paper was to review the basic structure, genetic polymorphism and ethnic difference of CYP2C9, CYP2C19, CYP3A4 and the influence to sulfonylurea metabolism.

Key words: CYP2C9, CYP2C19, CYP3A4, Sulfonylurea antidiabetic drugs, Drug metabolism

中图分类号:

R968

李赟, 何芳, 曾彩雯, 刘林林, 夏春华. CYP2C9、CYP2C19、CYP3A4基因多态性对磺脲类降糖药代谢的影响[J]. 中国临床药理学与治疗学, 2012, 17(5): 582-587.

LI Yun, HE Fang, ZENG Cai-wen, LIU Lin-lin, XIA Chun-hua. Effect of CYP2C9, CYP2C19, CYP3A4 polymorphism on metabolism of sulfonyluea antidiabetic drugs[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(5): 582-587.

参考文献

[1] Elliot DJ, Suharjono, Lewis BC, et al. Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination [J]. Br J Clin Pharmacol,2007, 64(4): 450-457.
[2] 黄作君, 黎月玲, 黄民. CYP2C19基因多态性与磺酰脲类降糖药药代动力学药效学相关性的研究进展[J]. 中国临床药理学与治疗学,2007, 12(2): 219-223.
[3] Ragia G, Petridis I, Christakidis D, et al. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas[J]. Pharmacogenomics, 2009, 10(11): 1781-1787.
[4] Gokalp O, Gunes A, Cam H, et al. Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting[J]. Eur J Clin Pharmacol, 2011, 67(12): 1223-1229.
[5] 赵树进, 袁进. CYP2C19基因多态性的分子学机制、基因型检测及对药物代谢的影响[J]. 广东医学, 2006, 27(8): 1268-1270.
[6] 陈騉, 王睿. 药物代谢酶细胞色素P450 2C9研究进展[J]. 中国临床药理学与治疗学, 2004, 9(6): 601-606.
[7] 严非,夏春华,熊玉卿. CYP2C19基因多态性对药物代谢的影响及其个体化用药[J]. 中国临床药理学与治疗学, 2010, 15(8): 949-952.
[8] Imai J, Ieiri I, Mamiya K. Polymorphism of the cytochrome P450(CYP)2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus[J]. Pharmacogenetics, 2000, 10(1): 85-92.
[9] 张志贤, 常福厚. 细胞色素P450 2C19基因多态性研究进展[J]. 中国公共卫生, 2010, 26(3): 365-366.
[10] 赵伟红, 陈枢青. 细胞色素P450 2C19基因多态性的研究进展[J]. 宁波大学学报:理工版, 2004, 17(2): 230-233.
[11] DeMorais CM, Wilkinson GR, Blaisdell J, et al . The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans [J]. J Biol Chem, 1994, 269 (22): 15419-15422.
[12] 付良青, 吴德政. 细胞色素氧化酶P450 2C19的研究进展[J]. 国外医学药学分册, 2001, 28(2): 74-78.
[13] 陈欣, 李玉珍, 方冀. CYP3A4代谢药物的特点及其多态性的研究现状[J]. 中国药房, 2010, 21(22): 2097-2098.
[14] Hu YF, Zhou HH. Contribution of genetic polymorphisms of the CYP3A4. CYP3A5 and MDRI genes to cyclosporine disposition [J]. Chin Pharmacol Bull, 2005, 21(3): 257-261.
[15] 穆殿平, 徐为人, 高仲阳. 细胞色素P450 3A4基因多态性及对药物代谢的影响[J]. 中国药学杂志, 2008, 43(6): 405-408.
[16] Sata F, Sapone A, Elizondo G, et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity[J]. Clin Pharmacol Ther, 2000, 67(1): 48-56.
[17] 周君霞, 沈行良. 细胞色素P450 2C9基因多态性影响药物代谢动力学的研究[J]. 临床荟萃, 2008, 23(12): 908-910.
[18] Xu H, Williams KM, Liauw WS, et al. Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide[J]. Br J Pharmacol, 2008, 153(7): 1579-1586.
[19] Zhang Y, Si D, Chen X, et al. Influence of CYP2C9 and CYP2C19 genetic Polymorphism on pharmacokinetics of gliclazide MR in Chinese subjects [J]. Br J Clin Pharmacol, 2007, 64(1): 67-74.
[20] Niemi M, Cascorbi I, Timm R, et al. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes[J]. Clin Pharmacol Ther, 2002, 72(3): 326-32.
[21] Kidd RS, Curry TB, Gallagher S, et al. Identification of a null allele of CYP2C9 in an African-American exhibiton toxicity to phenytoin[J]. Pharmacogenetics, 2001, 11(9): 803-808.
[22] 李健, 闻思远, 王睿, 等. 细胞色素P450 CYP2C9基因多态性对甲苯磺丁脲代谢动力学的影响[J]. 药学学报, 2005, 40(8): 695-699.
[23] 李明, 尹丽敏. 沿海汉族人群CYP2C9基因多态性与甲苯磺丁脲代谢活性关系[J]. 中国药物与临床, 2010, 10(2): 140-143.
[24] 张琦, 彭妙官, 蒋培培, 等. 磺酰脲类药物致2型糖尿病患者低血糖与CYP2C9基因型关系初步研究[J]. 药物不良反应杂志, 2008, 10(6): 387-391.
[25] 熊晓敏, 曾彩雯, 夏春华.细胞色素P4502C9基因多态性对健康人体内格列喹酮药代动力学的影响 [J]. 中国临床药理学杂志, 2011, 27 (10): 759-761.
[26] Wester MR, Lasker JM, Johnson EF, et al. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes[J]. Drug Metab Dispos, 2000, 28(3): 354-359.
[27] Tan B, Zhang YF, Chen XY, et al. The effects of CYP2C9 and CYP2C19 genetic polymorphi sms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects[J]. Eur J Clin Pharmacol, 2010, 66(2): 145-151.
[28] Holstein A, Hahn M, Patzer O, et al. Impact of clinical factors and CYP2C19 variants for the risk of severe sulfonylurea-induced hypoglycemia[J]. Eur J Clin Pharmacol, 2011, 67(5): 471-476.
[29] Naritiomi Y, Terashita S, Kagayama A. Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate[J]. Xenobiotica, 2004, 34(5): 415-427.
[30] Zhou L, Naraharisetti SB, Liu L, et al. Contributions of Human Cytochrome P450 Enzymes to Glyburide Metabolism[J]. Biopharm Drug Dispos, 2010, 31(4): 228-242.
[31] Lepper ER, Baker SD, Permenter M, et al. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients[J]. Clin Cancer Res, 2005, 11(20): 7398-7404.
[32] Henningsson A, Marsh S, Loos WJ, et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel[J]. Clin Cancer Res, 2005, 11(22): 8097-8104.
[33] Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos[J]. J Pharmacol Exp Ther, 2001, 299(3): 825-831.